NCT00438230View on ClinicalTrials.gov

Residual Vein Thrombosis Establishes the Optimal Duration of Oral Anticoagulants

PHASE4CompletedINTERVENTIONAL

Enrollment

250

Participants

Timeline

Start Date

November 30, 2003

Study Completion Date

September 30, 2006

Conditions

Deep Vein Thrombosis

Interventions

DRUG

Warfarin

All Listed Sponsors

lead

Azienda Ospedaliera Universitaria Policlinico

OTHER

NCT00438230 - Residual Vein Thrombosis Establishes the Optimal Duration of Oral Anticoagulants | Biotech Hunter | Biotech Hunter